Marshall Wace, LLP Y M Abs Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 49,225 shares of YMAB stock, worth $316,024. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,225
Previous 15,509
217.4%
Holding current value
$316,024
Previous $203,000
89.66%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding YMAB
# of Institutions
113Shares Held
26.9MCall Options Held
5.6KPut Options Held
900-
Paradigm Biocapital Advisors LP New York, NY4.24MShares$27.2 Million1.27% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$18.9 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.86MShares$18.4 Million12.11% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$14.1 Million1.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA2MShares$12.8 Million0.0% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $281M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...